Quantifying Plasma Levels of Transforming Growth Factor β1 in Idiopathic Pulmonary Fibrosis

Molina-Molina, María; Lario, Sergio; Luburich, Patricio; Ramírez, José; Carrión, María Teresa; Xaubet, Antoni

doi:10.1016/S1579-2129(06)60550-8

Article information

Abstract

Bibliography

Download PDF

Statistics

Objective

Transforming growth factor β1 (TGF-β1) is one of the key profibrotic mediators in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The purpose of this study was to investigate the prognostic value of quantifying TGF-β1 levels in patients with IPF.

Patients and methods

We conducted a prospective study of 29 IPF patients and 27 healthy controls. Enzyme-linked immunosorbent assays were used to quantify TGF-β1 levels.

Results

Mean (SD) TGF-β1 levels were significantly higher in the IPF patients than in the control subjects (11.1 [7.5] ng/mL vs 4 [2.4] ng/mL; P<.01). Weak inverse correlations were observed between TGF-β1 levels and both forced vital capacity and total lung capacity. Thirteen IPF patients were evaluated at 8 (1.2) months (range, 5–9 months). The mean TGF-β1 level was 18.2 (15) ng/mL and there were no significant differences with respect to the initial measurement of 11.1 (7.5) ng/mL.

No correlation was observed between changes in respiratory function and changes in TGF-β1 levels.

Conclusions

Although plasma levels of TGF-β1 were high in the patients with IPF, they do not appear to be a useful prognostic marker of disease activity or therapeutic response.

Key words:

Idiopathic pulmonary fibrosis

Interstitial pulmonary diseases

Transforming growth factor β1

Serum markers

Objetivo

El factor transformador del crecimiento β1 (TGF-β1) es uno de los mediadores fibrogénicos con más relevancia en la patogenia de la fibrosis pulmonar idiopática (FPI). El objetivo del estudio ha sido investigar el valor pronóstico de la determinación en plasma del TGF-β1 en la FPI.

Pacientes y métodos

Se ha realizado un estudio prospective en el que se incluyó a 29 pacientes con FPI y 27 controles sanos. La determinación del TGF-β1 se realizó mediante enzimoinmunoanálisis.

Resultados

La concentración de TGF-β1 de significativamente mayor en los pacientes con FPI que en los controles (media ± desviación estándar: 11,1 ± 7,5 frente a 4 ± 2,4 ng/ml; p < 0,01). Se observó una débil relación inversa de la concentración del TGF-β1 con los valores de la capacidad vital forzada y de la capacidad pulmonar total. Se evaluó a 13 pacientes con FPI a los 8 ± 1,2 meses (rango: 5–9 meses). La concentración de TGF-β1 fue de 18,2 ± 15 ng/ml, sin diferencias significativas respecto a la primera determinación (11,1 ± 7,5 ng/ml). No se observó ninguna relación entre los cambios evolutivos en la exploración funcional respiratoria y los cambios en la concentración de TGF-β1.

Conclusiones

Aunque la concentración plasmática de TGF-β1 está elevada en los pacientes con FPI, este parámetro no parece ser útil como marcador del pronóstico de la enfermedad ni de la respuesta terapéutica.

Palabras clave:

Fibrosis pulmonar idiopática

Enfermedades pulmonares intersticiales

Factor transformador del crecimiento β1

Marcadores séricos

Full text is only aviable in PDF

References

[1]

TE King, M Schwarz, K Brown, J Ose, T Coolí, J Waldron, et al.

Idiopathic pulmonary fibrosis. Relationship between histopathologic features and mortality.

Am J Respir Crit Care Med, 164 (2001), pp. 1025-1032

http://dx.doi.org/10.1164/ajrccm.164.6.2001056 | Medline

[2]

PW Noble, RJ Homer.

Idiopathic pulmonary fibrosis: new insights into pathogenesis.

Clin Chest Med, 25 (2004), pp. 749-758

http://dx.doi.org/10.1016/j.ccm.2004.04.003 | Medline

[3]

JM Fellrath, RM du Bois.

Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis.

Clin Exp Med, 3 (2003), pp. 65-83

http://dx.doi.org/10.1007/s10238-003-0010-3 | Medline

[4]

A Pardo, M Selman.

Idiopathic pulmonary fibrosis: new insights in its pathogenesis.

Int J Biochem Cell Biol, 34 (2002), pp. 1534-1538

Medline

[5]

ES White, MH Lazar, VJ Thannickal.

Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

J Pathol, 201 (2003), pp. 343-354

http://dx.doi.org/10.1002/path.1446 | Medline

[6]

C Ramos, M Montano, J García-Álvarez, V Ruiz, BD Uhal, M Selman, et al.

Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression.

Am J Respir Cell Mol Biol, 24 (2001), pp. 591-598

http://dx.doi.org/10.1165/ajrcmb.24.5.4333 | Medline

[7]

U Bartram, CP Speer.

The role of transforming growth factor beta in lung development and disease.

Chest, 125 (2004), pp. 754-765

Medline

[8]

TJ Broekelmann, AH Limper, TV Colby, JA McDonald.

Transforming growth factor beta-1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis.

Proc Natl Acad Sci U S A, 88 (1991), pp. 6642-6646

Medline

[9]

N Khalil, TV Parek, R O'Connor, N Antman, W Kepron, T Yehaulaeshet, et al.

Regulation of the effects of TGF-β1 by activation of latent TGF-β1 and differential expression of TGF-β1 receptors (TβR-I and Tβ-II) in idiopathic pulmonary fibrosis.

Thorax, 56 (2001), pp. 907-915

Medline

[10]

G Westergren-Thorsson, J Hernnas, B Sarnstrand, A Oldberg, D Heinegard, A Malmastrom.

Altered expression of small proteoglycans, collagen, and transforming growth factor-β1 in developing bleomycin-induced pulmonary fibrosis in rats.

J Clin Invest, 92 (1993), pp. 632-637

http://dx.doi.org/10.1172/JCI116631 | Medline

[11]

YD Xu, J Hua, A Mui, R O'Connor, G Grotendorst, N Khalil.

Release of biologically active TGF-beta1 by alveolar epithelial cells results in pulmonary fibrosis.

Am J Physiol Lung Cell Mol Physiol, 285 (2003), pp. L522-L526

http://dx.doi.org/10.1152/ajplung.00110.2003 | Medline

[12]

American Thoracic Society.

Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Am J Respir Crit Care Med, 161 (2000), pp. 646-664

http://dx.doi.org/10.1164/ajrccm.161.2.ats3-00 | Medline

[13]

A Xaubet, J Ancochea, R Blanquer, C Montero, F Morell, E Rodríguez, et al.

Diagnóstico y tratamiento de las enfermedades pulmonares intersticiales difusas.

Arch Bronconeumol, 39 (2003), pp. 580-600

Medline

[14]

SJ Yong, A Adlakha, AH Limper.

Circulating transforming growth factor-β1: a potential marker of disease activity during idiopathic pulmonary fibrosis.

Chest, 120 (2001), pp. 68S-70S

Medline

[15]

K Greene, TE King, Y Kuroki, B Bucher-Bartelson, GW Hunninghake, LS Newman, et al.

Serum surfactant proteins-A and D as biomarkers in idiopathic pulmonary fibrosis.

Eur Respir J, 19 (2002), pp. 439-446

Medline

[16]

H Ohnishi, A Yokoyama, K Kondo, H Hamada, M Abe, K Nishimura, et al.

Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.

Am J Respir Crit Care Med, 165 (2002), pp. 378-381

http://dx.doi.org/10.1164/ajrccm.165.3.2107134 | Medline

[17]

N Takahashi, T Fujishima, H Koba, S Murakami, K Kurokawa, Y Shibuya, et al.

Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent.

Am J Respir Crit Care Med, 162 (2000), pp. 1109-1114

http://dx.doi.org/10.1164/ajrccm.162.3.9910080 | Medline

[18]

SP Matusiewicz, IJ Williamson, PJ Sime, PH Brown, PR Wenham, GK Crompton, et al.

Plasma lactate dehydrogenase: a marker of disease activity in cryptogenic fibrosing alveolitis and extrinsic allergic alveolitis.

Eur Respir J, 6 (1993), pp. 1282-1286

Article | Medline

[19]

MW Ziegenhagen, P Zabel, G Zissel, M Schlaak, J Müller-Quernheim.

Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis and indicates disease activity.

Am J Respir Crit Care Med, 157 (1998), pp. 762-768

http://dx.doi.org/10.1164/ajrccm.157.3.9705014 | Medline

[20]

A Yokohama, N Kohno, H Hamada, M Sakatani, E Ueda, K Kondo, et al.

Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med, 158 (1998), pp. 1680-1684

http://dx.doi.org/10.1164/ajrccm.158.5.9803115 | Medline

[21]

S Hayashi, K Abe, H Matsuoka, S Goya, H Morishita, M Mori, et al.

Increased level of soluble E-selectin in the serum from patients with idiopathic pulmonary fibrosis.

Inflammation, 28 (2004), pp. 1-5

Medline

[22]

K Kuwano, T Maeyama, I Inoshima, K Ninomiya, N Hagimoto, M Yoshimi, et al.

Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.

Respirology, 7 (2002), pp. 15-21

Medline

[23]

J Ancochea, E Antón, A Casanova.

Nuevas estrategias terapéuticas en la fibrosis pulmonar idiopätica.

Arch Bronconeumol, 40 (2004), pp. 16-22

Medline

[24]

F Salez, P Gosset, MC Copin, CL Degros, AB Tonnel, B Wallaert.

Transforming growth factor-β1 in sarcoidosis.

Eur Respir J, 12 (1998), pp. 913-999

Medline

[25]

MR Awad, A El-Gamel, P Hasleton, DM Turner, PJ Sinnot, IV Hutchinson.

Genotype variation in the transforming growth factor β1 gene.

Transplantation, 66 (1998), pp. 1014-1020

Medline

[26]

A el-Gamel, M Awad, E Sim, P Haselton, N Yonan, J Egan, et al.

Transforming growth factor-β1 and lung allograft.

Eur J Cardiothoracic Surg, 13 (1998), pp. 424-430

[27]

A el-Gamel, M Awad, P Haselton, NA Yonan, JA Hutchinson, CS Campbell, et al.

Transforming growth factor-β genotype and lung allograft fibrosis.

J. Heart Lung Transplant, 18 (1999), pp. 517-523

Medline

[28]

A Xaubet, S Marín-Arguedas, S Lario, J Ancochea, F Morell, J Ruiz-Manzano, et al.

TGF beta-1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis.

Am J Respir Crit Care Med, 168 (2003), pp. 431-435

http://dx.doi.org/10.1164/rccm.200210-1165OC | Medline

[29]

MS Anscher, WP Peters, H Reisenbichler, W Petros, RL Jirtle.

Transforming growth factor-β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.

N Engl J Med, 328 (1993), pp. 1592-1598

http://dx.doi.org/10.1056/NEJM199306033282203 | Medline

This study was funded by grants from SEPAR: Fundación Respira 2000, FIS 00/371, and Red Respira V-2003-REDC 11 D-O.

Indexed in:

Follow us:

Subscribe:

Indexed in:

Follow us:

Subscribe:

Subscribe to our newsletter